Cargando…
Comparison of AMG 416 and cinacalcet in rodent models of uremia
BACKGROUND: AMG 416 is a novel peptide agonist of the calcium-sensing receptor (CaSR). This report describes the activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (SHPT) in patients with chroni...
Autores principales: | Walter, Sarah, Baruch, Amos, Alexander, Shawn T, Janes, Julie, Sho, Eiketsu, Dong, Jin, Yin, Qun, Maclean, Derek, Mendel, Dirk B, Karim, Felix, Johnson, Randolph M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030018/ https://www.ncbi.nlm.nih.gov/pubmed/24884838 http://dx.doi.org/10.1186/1471-2369-15-81 |
Ejemplares similares
-
Pharmacokinetics, Biotransformation, and Excretion of [(14)C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
por: Subramanian, Raju, et al.
Publicado: (2016) -
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
por: Martin, Kevin J., et al.
Publicado: (2014) -
Uremia
por: Low, J. H.
Publicado: (1883) -
Immune Dysfunction in Uremia—An Update
por: Cohen, Gerald, et al.
Publicado: (2012) -
Monocytes in Uremia
por: Girndt, Matthias, et al.
Publicado: (2020)